Vaccine Toxicity Studies Could Use Earlier FDA Input, Reviewer Suggests
Executive Summary
FDA may need to develop a mechanism for providing advice to sponsors on preclinical toxicity studies prior to the pre-IND meeting, FDA Office of Vaccines Scientific Reviewer Marion Gruber, PhD, suggested